Recursion Pharmaceuticals Inc [RXRX] stock is trading at $8.35, up 3.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The RXRX shares have gain 9.72% over the last week, with a monthly amount drifted -4.68%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock has seen the most recent analyst activity on May 22, 2023, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $8. Previously, Needham started tracking the stock with Buy rating on March 16, 2023, and set its price target to $17. On September 16, 2022, KeyBanc Capital Markets initiated with a Overweight rating and assigned a price target of $20 on the stock. BofA Securities downgraded its rating to a Neutral but stick to its price target of $10 on April 18, 2022. SVB Leerink downgraded its rating to a Mkt Perform but $10 remained the price target by the analyst firm on March 04, 2022. Berenberg started tracking with a Buy rating for this stock on September 21, 2021, and assigned it a price target of $37. In a note dated May 11, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $33 on this stock.
Recursion Pharmaceuticals Inc [RXRX] stock has fluctuated between $4.97 and $15.74 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $8.35 at the most recent close of the market. An investor can expect a potential return of 91.62% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
Recursion Pharmaceuticals Inc [NASDAQ:RXRX] reported sales of 46.23M for the trailing twelve months, which represents a growth of 13.68%. Gross Profit Margin for this corporation currently stands at -0.27% with Operating Profit Margin at -8.44%, Pretax Profit Margin comes in at -7.78%, and Net Profit Margin reading is -7.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.8 and Total Capital is -0.8. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.16 points at the first support level, and at 7.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.51, and for the 2nd resistance point, it is at 8.68.
Ratios To Look Out For
For context, Recursion Pharmaceuticals Inc’s Current Ratio is 4.65. On the other hand, the Quick Ratio is 4.65, and the Cash Ratio is 4.05. Considering the valuation of this stock, the price to sales ratio is 48.48, the price to book ratio is 5.10.
Transactions by insiders
Recent insider trading involved Borgeson Blake, Director, that happened on Jul 23 ’24 when 11447.0 shares were sold. Chief Executive Officer, Gibson Christopher completed a deal on Jul 11 ’24 to sell 50000.0 shares. Meanwhile, Chief Executive Officer Gibson Christopher sold 50000.0 shares on Jul 10 ’24.
